OmicScouts GmbH

Looking back on a remarkable year ✨   2024 – what a year it has been! A year full of exciting developments, new opportunities, and unforgettable moments. Together, we’ve achieved so much: Projects that challenged and inspired us, scientific advancements that enriched our portfolio, new processes that made our work more seamless, and a strong team spirit. 💪   But 2024 was about more than just work. It was a year of laughter, creativity, and celebrating the joy of coming together:   🌿 Enjoying nature and clearing our minds during a day of wanderlust 🎨 Unleashing our creativity while painting ceramics 🎄 Soaking up the festive atmosphere at the Christmas market 🥗 Sharing stories and strengthening our bonds over delicious meals   All of this reminds us of what truly matters: the people behind the projects. Each and every one of you, whether a colleague, collaborator or client, has made this year special to us - and for that, we say THANK YOU! 💙   Now, we’re looking ahead with excitement. 2025 – we’re ready for new adventures, exciting challenges, and many more moments to share.   We wish you all a wonderful holiday season, joyful celebrations, and a happy New Year! 🕯️🎁🎉   Here’s to a fantastic new chapter – together! 🥂

Antimicrobial resistance is a growing threat, with pathogens like Staphylococcus aureus and Plasmodium falciparum (Malaria) becoming increasingly resistant. To overcome this, new drug targets and chemical modulators must be identified and characterized.   That's exactly what our PhD students Lorenzo Bizzarri and Dominik Steinbrunn as well as visiting researchers Patricia Bravo and Antoine Lacour from the MepAnti network set out to do. Targeting the underexplored MEP pathway, they developed tailored assays to assess target engagement and selectivity of novel compounds in microbes. 🦠   Using MS-based Integral Solvent-induced Protein Precipitation (iSPP), or SideScout™, they were able to achieve: ✔️ Direct target engagement measurement in living cells, without altering the compound ✔️ Concurrent selectivity profiling via proteomics ✔️ High-throughput screening with minimal sample input—crucial for hard-to-grow pathogens   Now published in two articles in ACS Infectious Diseases, this research covers applications in multiple bacterial pathogens and P. falciparum. A terrific collaborative effort from the MepAnti project—congratulations to all authors @ Anna Hirsch from Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Thibaut Quennesson and Serge Van Calenbergh from Ghent University, Gabriella Ines Bianchino and Myriam Seemann from University of Strasbourg, Pascal Mäser and Matthias Rottmann from the Swiss Tropical and Public Health Institute! 🙌   At OmicScouts, we are proud to support the next generation of talented researchers in the MepAnti network while contributing to the development of novel tools to combat multi-resistant pathogens!   🧐 Interested in learning more about iSPP / SideScout™ in the context of your own projects? -> Reach out to us at info@omicscouts.com! Links to articles: https://lnkd.in/gN34dZyA https://lnkd.in/gpNKZZjM

🚀 Starting into a new week with strong impressions from last week´s EIMDD meeting on irreversible modulation in drug discovery, organized by the British Pharmacological Society and hosted by AstraZeneca in Cambridge! It was really insightful and fascinating to see the developments and new technologies related to covalent drugs from both, academia and industry, that show promise to pave the way for new, innovative medicines. Many thanks to all the great speakers such as Lyn Jones, Nir London, David Mann, Emma Grant, Brad L. Pentelute, Andrea Gohlke & team, Brent Martin, Ivan Cornella-Taracido, Megan Matthews, Daniel Nomura, and all other colleagues for the lively discussions! 👏 Our very own Christin Zasada, Head of Bioinformatics, contributed a great talk about our Protein Turnover AtlasTM and how knowledge on protein half-lives can aid covalent drug development. Meanwhile, Michael Zollo presented a poster showcasing our CysScout™ technology, which enables the chemoproteomic profiling of on-/off-targets of cysteine-directed covalent inhibitors. 👌 Many thanks again to all the organizers and contributors for this extraordinary event! #DrugDiscovery #DrugDevelopment #Pharma

We're excited to be attending the HUPO 2024! 🎉 Our team members Götz-Norman Hagemann, Raffaela Berger, Johanna Wallner, and Kathrin Grundner-Culemann will attend the 23rd Human Proteome Organization World Congress in Dresden, Germany, from October 20 to 24. Where to find us: • Götz will present his poster P-I-0204 on Monday, October 21 • Raffaela will present her poster P-I-0105 on Monday, October 21 • Johanna will present her poster P-II-0745 on Tuesday, October 22 • Kathrin will participate in the "Future of MSCoreSys – The Industry Perspective" discussion on Tuesday, October 22 at 12:30 PM in Seminar Room 2 They're eager to connect with fellow professionals and explore the latest advancements in proteomics. If you're interested in topics like target deconvolution, protein turnover analysis, mechanism of action studies, or any innovative (chemical) proteomics services, make sure to stop by during their sessions or say hello if you see them around the conference - we'd love to chat over a coffee about your latest projects and how we can collaborate.   www.omicscouts.com #HUPO2024 #Proteomics #DrugDiscovery

Great programme on the irreversible modulation of therapeutic targets at the EIMDD in Cambridge this week (https://lnkd.in/eM4y_knH)! 😍 Our Head of Bioinformatics Christin Zasada is going to contribute a presentation about the cellular half-life of protein targets and its impact on the efficacy and pharmacokinetics of irreversible drug modalities. Reach out, if you are interested in hearing more about cellular protein turnover or the elucidation of compound-target interactions, such as target identification, binding site identification or selectivity profiling! www.omicscouts.com // info@omicscouts.com #DrugDevelopment #Pharma #DrugDiscovery

Interesting article on the capital market portal GoingPublic, elaborating on how in the last 10 years 🎉 OmicScouts has been using (chemo)proteomic technologies to accelerate the development of therapeutics that are both, safe and efficacious.   Always at the forefront of novel developments and innovation, we thrive on emerging challenges and opportunities in drug discovery with a comprehensive range of solutions: From target deconvolution and selectivity screenings to customized mechanism of action analyses and specific data products such as the ProteinTurnoverAtlas™ - our top goal is to deliver data that enable decision making 🚀   Need help to understand your compounds and their interactions with biological systems? Come work with us: www.omicscouts.com // info@omicscouts.com   #DrugDevelopment #DrugSafety #Pharma

Great to see this published!! Congrats to our collaborators at Bayer and the DKFZ, in particular Gabriele Leder, Jeffrey Mowat and Rienk Offringa! MAP4K1 (also known as HPK1) is a an attractive immune-oncology target for inducing therapeutic T-cell responses in cancer patients! OmicScouts is proud of contributing to this excellent study, in which our KinomeScout™ technology enabled selectivity profiling of the lead compound BAY-405 across cellular kinases of relevant biological systems! Read more about our KinomeScout assay here: https://lnkd.in/dgpTRvGr #Bayer #DrugDiscovery #Proteomics

Meet OmicScouts BD to talk about target deconvolution, target occupancy studies and all new pharmacological interventions: RNAi, degraders / mol. glues and PROTACS, or any other needs for (chemical) proteomics services. You can also reach out to us via LinkedIn or at info@omicscouts.com

Who will be at the EFMC-ISMC in Rome next week? Looking forward to seeing you there! If you´re wondering about target deconvolution, protein turnover or MoA analysis, let´s meet in the exhibition area and talk (chemo) proteomics! www.omicscouts.com // info@omicscouts.com #EFMC #MedicinalChemistry #DrugDiscovery

Great discussion and fantastic science at the ELRIG Research & Innovation conference in Manchester. #ELRIG #RI2024